Abstract library

6 results for "Fleming".
#870 Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#1068 Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#1333 Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period
Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (p<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg tid after Wk 12. The extension phase (Wk 13 to Wk 48) is still ongoing
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Dieter Hörsch
Authors: Hörsch D, Kulke M, Caplin M, Anthony L, ...
#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome
Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Lowell Anthony
Keywords: serotonin, diarrhea
#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease
Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Pablo Lapuerta
Authors: Lapuerta P, Kulke M H, Pavel M, Biran T, ...
Keywords: serotonin, 5-HIAA
#1942 Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
Introduction: TELECAST assessed telotristat ethyl (TE), a tryptophan hydroxylase inhibitor, in patients (pts) with carcinoid syndrome (CS) with ≥1 CS symptom/sign and a mean 2.5 bowel movements (BMs) per day. Pts were somatostatin analog treated (89%), with gastrointestinal (90%; [diarrhea, 70%]) and cardiac disorders (42%), including carcinoid heart disease. At Week (W) 12, TE (250 and 500 mg 3×/day; tid) significantly reduced urinary 5-hydroxyindoleacetic acid (u5-HIAA) and BMs/day vs placebo (pbo) (p≤0.008). After W12, pts crossed over to an open-label extension (OLE) with TE 500 mg tid (W13–48).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel
Keywords: serotonin, safety